Stock comparison
Halozyme Therapeutics
Tactile Systems Technology
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
TCMD
Tactile Systems Technology
Market cap
$561.65M
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HALO | TCMD | Winner |
|---|---|---|---|
| Warren Buffett | 79B | 54D | HALO |
| Benjamin Graham | 83A | 55D | HALO |
| Philip Fisher | 65B | 48D | HALO |
| Peter Lynch | 53D | 38D | HALO |
| Joel Greenblatt | 40D | 30F | HALO |
| Charlie Munger | 80C | 41D | HALO |
| Terry Smith | 84A | 47D | HALO |
Side-by-side metrics
| Metric | HALO | TCMD |
|---|---|---|
| Market cap | $8.1B | $561.65M |
| P/E (TTM) | 24.0x | 26.6x |
| EV/EBIT | 10.2x | 16.4x |
| ROIC (TTM) | 23.65% | 7.93% |
| Gross margin | 81.24% | 75.68% |
| Net margin | 23.13% | 5.91% |
| Revenue CAGR 5y | 33.23% | 12.18% |
| EPS CAGR 5y | -1.98% | - |
| Debt / Equity | 1.0x | 0.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HALO leads on
- Market cap$8.1Bvs $561.65M+93%
- Net margin23.13%vs 5.91%+74%
- ROIC (TTM)23.65%vs 7.93%+66%
- Revenue CAGR 5y33.23%vs 12.18%+63%
TCMD leads on
- Debt / Equity0.1xvs 1.0x+93%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.